gilead recent announc ceo chairman
step new manag announc
result clamor decid analyz data share perform
commerci value-cr potenti pipelin strength risk-adjust
return versu peer truli uniqu profil rank close top
almost everi categori except share price return past year
futur potenti current pipelin project believ new ceo must
deliv nash immunolog add high-valu project judici
maintain esprit de corp
analyst journalist struggl find appropri word end
era specul start instantan mani potenti contend
name toss ring simpli note save live
countless hiv- hcv-infect patient among other simplifi treatment
option provid superior sharehold return progress
last share price sales/earn trajectori
among best peer group see unfortun savvi
pharmasset purchas becom anvil around sharehold
neck drag perform expos proud compani cultur unus
flounder initi posit struggl
refocus mindset
mindsetw believei focus late-stag nash
immunolog pipelin project creat futur valu third-parti analys
indic nash immunolog low expect even
futur product sale fact rank first value-cr
recent launch product bottom quartil futur pipelin return
bet qualiti internal/extern project minim failur rate
compani rank togeth equal cumul sale recent
launch product respect peer like celgen celg ozanimod roch
rog vx lampalizumab signific recent late-stag stumbl unlik
past year sub-optim believ
board lose sight fact underpin compani
rock solid next year crucial get long-suff
sharehold mojo back remain neutral admir esprit de
corp alright
medicin area unmet medic
need gilead portfolio product
pipelin investig drug
includ treatment hiv/aid liver
inflammatori
respiratori diseas cardiovascular
analyst certif import disclosur see disclosur
initi coverag gilead perform rate
sinc launch hcv product late
share roller coaster ride
street first underappreci potenti hcv
surpris franchis declin worst-off patient
cure hcv busi stabilizng near term resurg
hiv busi growth addit kite axi-cel nash
off-set flat sales/non-gaap ep
opco model averag rel peer-group metric
believ risk/reward balanc
hcv sale declin slowli stabil
hiv busi launch taf-bas regimen bic/f/taf
make hiv solid growth busi
yescarta axi-cel launch across us eu meet
expect sale
nash franchis lead product selonsertib approv
market
cardiovascular/oth busi sale reduc
due gener competit
non-gaap oper margin declin
nhl filgotinib phase data ra
phase data nash pbc psc yescarta
year follow data phase data cle
selonsertib phase
data nash
data nash
complet list catalyst note
hcv sale trough next one two year stable/up
patient diagnos treat
hiv busi outperform expect
axi-cel us/eu launch beat reduc expect provid
abl start grow margin onward
hcv busi continu declin precipit rate near
hiv busi growth minim best next two five year
axi-cel us/eu launch underperform reduc expect due
car-t side-effect manufactur reimburs concern
nash franchis gain traction clinic data
mediocr best even among nash patient fibrosi
exhibit sale growth compound-annual-growth-rate vs amgn/biib/celg/nbi
exhibit adj ebitda growth compound-annual-growth-rate vs amgn/biib/celg/nbi
exhibit valu creation recent launch pipelin product
exhibit valu creation pipelin product
exhibit top recent launch pipelin valu creation strategi
exhibit valu creation advanc therapi
exhibit sale risk patent expiri
exhibit sale growth risk pipelin concentr
exhibit current valuabl project rank net present valu
exhibit valuabl project rank npv june sinc approv launch
exhibit valuabl project rank npv june sinc suffer setback
exhibit alright
epclusa- vosevi- hcv descovy- vemlidy- bic/ftc/taf- hiv total axi-cel- selonsirtib- total total product inc
statement million except per product royalti contract total good research sell gener non-gaap oper non-gaap oper non-gaap incom expens interest non-gaap incom incom incom tax non-gaap net net loss attribut non control net incom attribut dilut dilut share adjust comp gross oper incom tax perform na
bloomberg price
